Cardiovascular issues in hypogonadism and testosterone therapy.

Area of Science:

• Endocrinology
• Cardiology
• Metabolic Syndrome

Background:

• Vascular cells possess sex steroid hormone receptors, indicating testosterone's potential vascular effects.
• Hypogonadism is linked to adverse metabolic and cardiovascular risk factors, including obesity, insulin resistance, and dyslipidemia.
• Observational studies present conflicting data on the association between low testosterone and cardiovascular disease (CVD).

Purpose of the Study:

• To systematically review cardiovascular issues associated with hypogonadism and testosterone therapy.
• To evaluate the impact of testosterone therapy on cardiovascular risk factors and disease.

Main Methods:

• A systematic literature search was performed to gather relevant studies.
• Analysis included observational and interventional studies investigating testosterone's cardiovascular effects.

Main Results:

• Interventional studies show no direct long-term link between testosterone therapy and CVD.
• Short-term data suggest potential cardiovascular benefits, with improvements in insulin sensitivity, obesity, and lipid profiles (total cholesterol, LDL).
• Testosterone therapy's effect on HDL cholesterol is variable and may not be atherogenic.

Conclusions:

• Cardiovascular effects of testosterone therapy appear neutral to beneficial in men with diagnosed hypogonadism and CVD.
• Caution is advised regarding hematocrit increases, particularly in heart failure patients.
• Evidence does not support testosterone therapy for cardiovascular benefit in aging men without hypogonadism.